share_log

4: Statement of changes in beneficial ownership of securities-Officer Byrnes Michael

4: Statement of changes in beneficial ownership of securities-Officer Byrnes Michael

4：持股變動聲明-高管 Byrnes Michael
美股sec公告 ·  05/17 16:03
Moomoo AI 已提取核心訊息
Michael Byrnes, the Chief Financial Officer of eFFECTOR Therapeutics, Inc. (EFTR), completed a purchase of 1,387 shares of common stock on May 15, 2024. The transaction was carried out at a price of $1.683 per share, resulting in a total investment of approximately $2,335. The acquisition was made directly and is part of a grant, award, or other acquisition. Following this transaction, Byrnes holds a total of 3,117 shares in the company. The transaction reflects the CFO's growing stake in eFFECTOR Therapeutics and could be a signal of confidence in the company's future prospects.
Michael Byrnes, the Chief Financial Officer of eFFECTOR Therapeutics, Inc. (EFTR), completed a purchase of 1,387 shares of common stock on May 15, 2024. The transaction was carried out at a price of $1.683 per share, resulting in a total investment of approximately $2,335. The acquisition was made directly and is part of a grant, award, or other acquisition. Following this transaction, Byrnes holds a total of 3,117 shares in the company. The transaction reflects the CFO's growing stake in eFFECTOR Therapeutics and could be a signal of confidence in the company's future prospects.
Effector Therapeutics, Inc.（EFTR）的首席財務官邁克爾·伯恩斯於2024年5月15日完成了對1387股普通股的購買。該交易以每股1.683美元的價格進行，總投資約爲2335美元。此次收購是直接進行的，是撥款、獎勵或其他收購的一部分。在這筆交易之後，伯恩斯共持有該公司3,117股股份。該交易反映了首席財務官在Effector Therapeutics的股份不斷增加，可能表明了對公司未來前景的信心。
Effector Therapeutics, Inc.（EFTR）的首席財務官邁克爾·伯恩斯於2024年5月15日完成了對1387股普通股的購買。該交易以每股1.683美元的價格進行，總投資約爲2335美元。此次收購是直接進行的，是撥款、獎勵或其他收購的一部分。在這筆交易之後，伯恩斯共持有該公司3,117股股份。該交易反映了首席財務官在Effector Therapeutics的股份不斷增加，可能表明了對公司未來前景的信心。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息